Ursodeoxycholic acid for the prevention of gallstone disease after bariatric surgery

Cover Page

Cite item

Full Text

Abstract

Background: The development of gallstone disease (GSD) after bariatric surgery is a significant problem. The prophylactic effect of ursodeoxycholic acid (UDCA) preparations on the occurrence of cholelithiasis after gastric bypass and longitudinal gastrectomy has been studied. Aims: The aim of the study was to evaluate the effectiveness of ursodeoxycholic acid preparations in the prevention of cholelithiasis in patients after bariatric surgery. Methods: The results of a year-long follow-up for 128 patients after bariatric surgery were analyzed. In 68 patients, the prophylaxis of the gallstone disease development was not performed. 60 patients took a daily 500 mg dose of UDCA orally. Results: Cholelithiasis had developed in 17 (25%) patients who did not undergo the prophylaxis of cholelithiasis. Of these, 10 (14.7%) underwent cholecystectomy. Among those patients who took UDCA drugs, stones in the gallbladder were found in 7 (11.6%), and only one patient (1.7%) required a surgical treatment. Conclusion: UDCA administration during the first year after bariatric surgery in the amount of 500 mg per day significantly reduces the likelihood of the de novo cholelithiasis development. The medical prophylaxis of gallstone disease should be included in the standards of bariatric patients' management.

About the authors

Alexander V. Smirnov

Federal Scientific and Clinical Center for Specialized Medical Assistance and Medical Technologies of the Federal Medical Biological Agency

Author for correspondence.
Email: alvsmirnov@mail.ru
ORCID iD: 0000-0003-3897-8306
SPIN-code: 5619-1151

MD, Cand. Sci (Med.)

Russian Federation, 28, Orekhovy Boulevard, Moscow, 115682

Yuri V. Ivanov

Federal Scientific and Clinical Center for Specialized Medical Assistance and Medical Technologies of the Federal Medical Biological Agency

Email: ivanovkb83@yandex.ru
ORCID iD: 0000-0001-6209-4194
SPIN-code: 3240-4335

MD, Dr. Sci. (Med.), Professor

Russian Federation, 28, Orekhovy Boulevard, Moscow, 115682

Vladimir R. Stankevich

Federal Scientific and Clinical Center for Specialized Medical Assistance and Medical Technologies of the Federal Medical Biological Agency

Email: v-stankevich@yandex.ru
ORCID iD: 0000-0002-8620-8755
Russian Federation, 28, Orekhovy Boulevard, Moscow, 115682

Valentin I. Sharobaro

Federal Scientific and Clinical Center for Specialized Medical Assistance and Medical Technologies of the Federal Medical Biological Agency

Email: sharobarovi@mail.ru
ORCID iD: 0000-0002-1510-9047
SPIN-code: 3677-0208

MD, Dr. Sci. (Med.), Professor

Russian Federation, 28, Orekhovy Boulevard, Moscow, 115682

Eugen A. Velichko

Federal Scientific and Clinical Center for Specialized Medical Assistance and Medical Technologies of the Federal Medical Biological Agency

Email: velichko_eugen@mail.ru
ORCID iD: 0000-0002-0297-8155
SPIN-code: 9817-2850

MD, Cand. Sci (Med.)

Russian Federation, 28, Orekhovy Boulevard, Moscow, 115682

References

  1. Смирнов А.В., Станкевич В.Р., Панченков Д.Н., и др. Симультанные операции в бариатрической хирургии // Клиническая практика. 2020. Т. 11, № 4. С. 55-63. [Smirnov AV, Stankevich VR, Panchenkov DN, et al. Simultaneous operations in bariatric surgery. Journal of Clinical Practice. 2020;11(4):55-63. (In Russ).] doi: 10.17816/clinpract58047
  2. Altieri MS, Yang J, Nie L, et al. Incidence of cholecystectomy after bariatric surgery. Surg Obes Relat Dis. 2018;14(7):992-996. doi: 10.1016/j.soard.2018.03.028
  3. Wanjura V, Szabo E, Osterberg J, et al. Morbidity of cholecystectomy and gastric bypass in a national database. Br J Surg. 2018;105(1):121-127. doi: 10.1002/bjs.10666
  4. Amstutz S, Michel JM, Kopp S, Egger B. Potential benefits of prophylactic cholecystectomy in patients undergoing bariatric bypass surgery. Obes Surg. 2015;25(11):2054-2060. doi: 10.1007/s11695-015-1650-6
  5. Festi D, Villanova N, Colecchia A. Risk factors for gallstone formation during weight loss. Clin Gastroenterol Hepatol. 2015;13(3):613. doi: 10.1016/j.cgh.2014.08.010
  6. Williams C, Gowan R, Perey BJ. A double-blind placebo-controlled trial of ursodeoxycholic acid in the prevention of gallstones during weight loss after vertical banded gastroplasty. Obes Surg. 1993;3(3):257-259. doi: 10.1381/096089293765559278
  7. Sakran N, Dar R, Assalia A, et al. The use of Ursolit for gallstone prophylaxis following bariatric surgery: a random-ized-controlled trial. Updates Surg. 2020;72(4):1125-1133. doi: 10.1007/s13304-020-00850-2
  8. Pizza F, D’Antonio D, Lucido FS, et al. The role of ursodeoxycholic acid (UDCA) in cholelithiasis management after one anastomosis gastric bypass (OAGB) for morbid obesity: results of a monocentric randomized controlled trial. Obes Surg. 2020;30(11):4315-4324. doi: 10.1007/s11695-020-04801-z
  9. Vural A, Goksu K, Kahraman AN, et al. Increased gallstone formation after sleeve gastrectomy and the preventive role of ursodeoxycholic acid. Acta Gastroenterol Belg. 2020;83(1):33-38.
  10. Sen O, Turkcapar AG, Yerdel MA. Cholelithiasis after sleeve gastrectomy and effectiveness of ursodeoxycholic acid treatment. J Laparoendosc Adv Surg Tech A. 2020;30(11):1150-1152. doi: 10.1089/lap.2020.0077
  11. Talha A, Abdelbaki T, Farouk A, et al. Cholelithiasis after bariatric surgery, incidence, and prophylaxis: randomized controlled trial. Surg Endosc. 2020;34(12):5331-5337. doi: 10.1007/s00464-019-07323-7
  12. Machado FH, Castro Filho HF, Babadopulos RF, et al. Ursodeoxycholic acid in the prevention of gallstones in patients subjected to Roux-en-Y gastric bypass1. Acta Cir Bras. 2019;34(1):e20190010000009. doi: 10.1590/s0102-865020190010000009
  13. Coupaye M, Calabrese D, Sami O, et al. Evaluation of incidence of cholelithiasis after bariatric surgery in subjects treated or not treated with ursodeoxycholic acid. Surg Obes Relat Dis. 2017;13(4):681-685. doi: 10.1016/j.soard.2016.11.022
  14. Abdallah E, Emile SH, Elfeki H, et al. Role of ursodeoxycholic acid in the prevention of gallstone formation after laparoscopic sleeve gastrectomy. Surg Today. 2017;47(7):844-850. doi: 10.1007/s00595-016-1446-x
  15. Adams LB, Chang C, Pope J, et al. Randomized, prospective comparison of ursodeoxycholic acid for the prevention of gallstones after sleeve gastrectomy. Obes Surg. 2016;26(5):990-994. doi: 10.1007/s11695-015-1858-5
  16. Miller K, Hell E, Lang B, Lengauer E. Gallstone formation prophylaxis after gastric restrictive procedures for weight loss: a randomized double-blind placebo-controlled trial. Ann Surg. 2003;238(5):697-702. doi: 10.1097/01.sla.0000094305.77843.cf
  17. Sugerman HJ, Brewer WH, Shiffman ML, et al. A multicenter, placebo-controlled, randomized, double-blind, prospective trial of prophylactic ursodiol for the prevention of gallstone formation following gastric-bypass-induced rapid weight loss. Am J Surg. 1995;169(1):91-96; discussion 96-97. doi: 10.1016/s0002-9610(99)80115-9
  18. Della Penna A, Lange J, Hilbert J, et al. Ursodeoxycholic acid for 6 months after bariatric surgery is impacting gallstone associated morbidity in patients with preoperative asymptomatic gallstones. Obes Surg. 2019;29(4):1216-1221. doi: 10.1007/s11695-018-03651-0
  19. Doulamis IP, Michalopoulos G, Boikou V, et al. Concomitant cholecystectomy during bariatric surgery: The jury is still out. Am J Surg. 2019;218(2):401-410. doi: 10.1016/j.amjsurg.2019.02.0061.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. The number of post- bariatric surgery patients with cholelithiasis, %.

Download (51KB)
Indexing metadata

Copyright (c) 2021 Smirnov A.V., Ivanov Y.V., Stankevich V.R., Sharobaro V.I., Velichko E.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies